
Dec 19 (Reuters) - Galectin Therapeutics Inc GALT.O:
GALECTIN THERAPEUTICS PROVIDES REGULATORY UPDATE FOLLOWING FDA WRITTEN RESPONSE AND ANNOUNCES AN ADDITIONAL $10 MILLION LINE OF CREDIT FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES THROUGH MARCH 2027
GALECTIN THERAPEUTICS INC - TO PURSUE FOLLOW-UP TYPE C MEETING